Literature DB >> 7221396

The assessment of disease activity in rheumatoid arthritis using a multivariate analysis.

R K Mallya, B E Mace.   

Abstract

A simple method of assessing 'index of disease activity' (IDA) in rheumatoid arthritis (RA) using a multivariate analysis (MVA) comprising morning stiffness (MS), pain scale (PS), grip strength (GS), articular index (AI), haemoglobin (Hb) and erythrocyte sedimentation rate (ESR) is described. The IDA of 99 patients with RA was assessed using MVA. The method could be used reliably and readily for random or longitudinal assessment, in drug trials and for comparing disease activity with other objective indices.

Entities:  

Mesh：

Substances：

Year:  1981        PMID： 7221396     DOI： 10.1093/rheumatology/20.1.14

Source DB:  PubMed          Journal:  Rheumatol Rehabil        ISSN： 0300-3396


  51 in total

1.  Comparison of two approaches to measuring change in health status in rheumatoid arthritis: the Health Assessment Questionnaire (HAQ) and modified HAQ.

Authors:  S Ziebland; R Fitzpatrick; C Jenkinson; A Mowat; A Mowat
Journal:  Ann Rheum Dis       Date:  1992-11       Impact factor: 19.103

Review 2.  What should we hope to achieve when treating rheumatoid arthritis?

Authors:  D L Scott; T D Spector; T Pullar; B McConkey
Journal:  Ann Rheum Dis       Date:  1989-03       Impact factor: 19.103

Review 3.  Impairment measures in rheumatic disorders for rehabilitation medicine and allied health care: a systematic review.

Authors:  Raymond A H M Swinkels; Lex M Bouter; Rob A B Oostendorp; Cornelia H M van den Ende
Journal:  Rheumatol Int       Date:  2005-06-24       Impact factor: 2.631

4.  A three year follow up of patients allocated to placebo, or oral or injectable gold therapy for rheumatoid arthritis.

Authors:  H A Capell; D Lewis; J Carey
Journal:  Ann Rheum Dis       Date:  1986-09       Impact factor: 19.103

5.  Early and late changes in sulphydryl group and copper protein concentrations and activities during drug treatment with aurothiomalate and auranofin.

Authors:  K J Rae; C N Mackay; C J McNeil; D H Brown; W E Smith; D Lewis; H A Capell
Journal:  Ann Rheum Dis       Date:  1986-10       Impact factor: 19.103

6.  Can we develop simple response criteria for slow acting antirheumatic drugs?

Authors:  D L Scott; J E Dacre; A Greenwood; L Treasure; E C Huskisson
Journal:  Ann Rheum Dis       Date:  1990-03       Impact factor: 19.103

7.  Free thiomalate levels in patients with rheumatoid arthritis treated with disodium aurothiomalate: relationship to clinical outcome of therapy.

Authors:  S R Rudge; D Perrett; A J Swannell
Journal:  Ann Rheum Dis       Date:  1984-10       Impact factor: 19.103

8.  Does the serum level of IgA-alpha-1-antitrypsin complex correlate with radiological progression in early rheumatoid arthritis? A 3-year follow-up study.

Authors:  J K Lacki; T Schochat; W Porawaska; S H Mackiewicz; W Müller
Journal:  Rheumatol Int       Date:  1995       Impact factor: 2.631

9.  Oral gold: a comparison with placebo and with intramuscular sodium aurothiomalate.

Authors:  D Lewis; H A Capell
Journal:  Clin Rheumatol       Date:  1984-03       Impact factor: 2.980

10.  Serum ferritin and free erythrocyte protoporphyrin in rheumatoid arthritis.

Authors:  P Hannonen; T Möttönen; M Oka
Journal:  Rheumatol Int       Date:  1986       Impact factor: 2.631
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.